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a b s t r a c t
Uncontrolled ﬁbrosis in organs like heart, kidney, liver and lung is detrimental and may lead to end-stage
organ failure. Currently there is no effective treatment for ﬁbrotic disorders. Transforming growth factor
(TGF)-β has a fundamental role in orchestrating the process of ﬁbrogenesis; however, interventions
directly targeting TGF-β would have undesired systemic side effects due to the multiple physiological
functions of TGF-β. Further characterization of the downstream signaling pathway(s) involved in TGF-β-
mediated ﬁbrosis may lead to discovery of novel treatment strategies for ﬁbrotic disorders. Accumulating
evidence suggests that Nox4 NADPH oxidase may be an important downstream effector in mediating
TGF-β-induced ﬁbrosis, while NADPH oxidase-dependent redox signaling may in turn regulate TGF-β/
Smad signaling in a feed-forward manner. It is proposed that pharmacological inhibition of the Nox4
function may represent a novel approach in treatment of ﬁbrotic disorders.
& 2014 The Authors. Published by Elsevier B.V. All rights reserved.
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TGF-β and ﬁbrotic disorders
Fibrosis is caused by uncontrolled wound healing responses
during tissue repair in pathological conditions such as myocardial
infarction, idiopathic pulmonary ﬁbrosis, hepatitis, and chronic
kidney disease [1]. Fibrotic scars are characterized by accumulation
of contractile matrix proteins and tend to compromise normal
tissue functions. One of the major proﬁbrotic cytokines orchestrat-
ing ﬁbrogenesis is transforming growth factor (TGF)-β (see Fig. 1).
More than two decades ago it was shown that an exogenous
application of TGF-β to incisional wounds accelerated production
of collagen and improved the wound healing efﬁciency [2]. TGF-β is
a multifunctional protein, and one of its major biological effects
is to promote the recruitment of ﬁbroblasts to wound site and
synthesis of structural matrix proteins [3]; both processes are
crucial to ﬁbrogenesis (Fig. 1). TGF-β is produced by inﬁltrating
inﬂammatory cells (for example macrophages), parenchymal cells,
and platelets during tissue repair [4,5]. The proﬁbrotic activity
of TGF-β can be further regulated by other endogenous factors
such as angiotensin II [6].
A major source of ﬁbroblasts identiﬁed in scarred tissues is
proliferation and migration of resident ﬁbroblasts to the injured
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site, partially stimulated by TGF-β [7,8], while other sources may
include epithelial to mesenchymal transition (EMT) and cells
derived from the bone marrow [9]. Iwano et al. used bone marrow
chimeras and transgenic reporter mice to trace origins of ﬁbro-
blasts in ﬁbrotic kidneys; two populations of ﬁbroblasts have been
identiﬁed, with the majority being derived from local EMT
and a minor proportion being from the bone marrow [9]. TGF-β
mediates EMT in a variety of organs including lung, liver, kidney,
heart and eye [10]. Endothelial to mesenchymal transition
mediated by TGF-β has also been observed and may play a role
in cardiac ﬁbrosis [11]. Hence, TGF-β is a crucial mediator for the
generation and mobilization of ﬁbroblasts required for ﬁbrogen-
esis. Fibroblasts identiﬁed in scarred tissues are responsible for the
production of matrix proteins [12]. TGF-β promotes accumulation
of these proteins by inducing a phenotypic change of ﬁbroblast to
a highly efﬁcient matrix-producing type termed myoﬁbroblast [3].
To prevent degradation of the newly synthesized matrix proteins,
TGF-β also inhibits expression of matrix catabolizing enzymes
such as matrix metalloproteinases, and induces expression of
matrix metalloproteinase inhibitors such as the tissue inhibitor
of metalloproteinase [4].
Interventions directly targeting TGF-β would have undesired
systemic side effects due to the multiple physiological functions of
TGF-β [13,14]. Therefore, further characterization of the down-
stream signaling pathway(s) involved in TGF-β-induced ﬁbrotic
process may provide useful information in the discovery of novel
treatment strategies for various ﬁbrotic disorders.
Involvement of NADPH oxidase in TGF-β-mediated proﬁbrotic
effects
Accumulative evidence highlights the involvement of NADPH
oxidase-dependent redox signaling in the proﬁbrotic responses
mediated by TGF-β [15]. Five isoforms of the Nox catalytic subunit,
namely Nox1, Nox2, Nox3, Nox4 and Nox5, have been identiﬁed [16].
The prototypical NADPH oxidase is composed of the membrane-
bound Nox and p22phox, as well as the cytosolic subunits p40phox,
p47phox, p67phox and a small GTPase Rac (Fig. 2 insert) [16].
Whereas all of the Nox isoforms except for Nox3 have been shown
to be expressed in ﬁbroblasts from different organs (including blood
vessels, heart, lung and kidney), current evidence suggests that
the Nox4 type NADPH oxidase may have a pivotal role in mediating
TGF-β-induced proﬁbrotic responses [15,17–22].
TGF-β increased Nox4 gene expression without effects on Nox1,
Nox2 or Nox5 in human cardiac ﬁbroblasts [18]. Treatment with
siRNA against Nox4 suppressed expression of TGF-β target genes
including ﬁbronectin, collagen I, α-smooth muscle actin (α-SMA,
a marker of myoﬁbroblast), and connective tissue growth factor,
indicating that Nox4 was involved in TGF-β-induced differentia-
tion of cardiac ﬁbroblasts to myoﬁbroblasts [18]. In renal tubular
epithelial cells, Rhyu et al. showed that inhibition of NADPH
oxidase activity with the non-selective Nox inhibitor DPI sup-
pressed EMT and matrix protein production [23,24]. In a recent
study, we showed that in mouse cardiac ﬁbroblasts, TGF-β-
stimulated collagen synthesis and myoﬁbroblast differentiation
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Fig. 1. How TGF-β stimulates ﬁbrotic responses during tissue repair. TGF-β is released by platelets, parenchymal cells and macrophages or its activity stimulated by
endogenous factors such as angiotensin II. Under the inﬂuence of TGF-β, proliferation and migration of resident ﬁbroblasts and the process of epithelial to mesenchymal
transition (EMT) occur, while ﬁbroblasts differentiate into myoﬁbroblasts in the wound site. Differentiated myoﬁbroblasts have a higher efﬁciency in synthesizing
extracellular matrix proteins. Accumulation of extracellular matrix is enhanced by the inhibitory and stimulatory effects of TGF-β on expression of matrix metalloproteases
and their inhibitors respectively.
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were abrogated by EUK-134 (a scavenger of both superoxide and
hydrogen peroxide) or a dominant negative form of Nox4 [17].
Such modulating effects of Nox4 in TGF-β-mediated collagen
expression have also been observed in fetal lung mesenchymal
cells [19], pulmonary ﬁbroblasts [25], kidney ﬁbroblasts [20] and
liver stellate cells [26]; all of these cells are engaged in the
development of ﬁbrosis in the affected organs. Moreover, there is
evidence showing that Nox4 mRNA and protein are increased in
pulmonary ﬁbroblasts isolated from patients with idiopathic
pulmonary ﬁbrosis, and the Nox4 expression level correlates with
expressions of procollagen I and α-SMA [25].
Amara et al. showed that targeted gene silencing of Nox4 with
tracheal administration of siRNA suppressed bleomycin-induced
pulmonary ﬁbrosis in mice [25]. Similarly, Carnesecchi et al.
reported that bleomycin-induced pulmonary ﬁbrosis was pre-
vented in Nox4 knockout mice, and this protective effect of Nox4
deﬁciency was attributable to a decrease in epithelial cell apopto-
sis induced by TGF-β [27]. Moreover, we used a mouse model of
subcutaneous sponge implantation and demonstrated that local
inhibition of Nox4 expression with RNA interference suppressed
the stimulatory effects of TGF-β on collagen accumulation in vivo
[17]. These in vitro and in vivo ﬁndings support the notion that
Nox4 has a pivotal role in mediating the proﬁbrotic actions of
TGF-β (Fig. 2).
Currently, a challenge is that we lack isoform-speciﬁc NADPH
oxidase inhibitors. GKT-136901 is an orally active selective inhi-
bitor of Nox1 and Nox4 [28], which has been shown to be able to
suppress liver ﬁbrosis induced by bile duct ligation [29]. Jarman
et al. recently showed that oral treatment with a putative Nox4
inhibitor known as compound 88 attenuated bleomycin-induced
lung ﬁbrosis in rats and TGF-β-induced induction of procollagen
and α-SMA expression in human pulmonary ﬁbroblasts [30].
These studies suggest that pharmacological inhibition of the
Nox4 function may represent a novel strategy in treatment of
ﬁbrotic disorders.
Redox modulation of TGF-β signaling
In addition to a potential role of NADPH oxidase as downstream
mediators in TGF-β-induced proﬁbrotic effects, there is also evi-
dence suggesting that redox pathways may regulate TGF-β/Smad
signaling in a feed-forward manner. For example, using cell-free
assays people have shown that irradiation or ion-catalyzed reactive
oxygen species (ROS) formation elicits conversion of the latent form
of TGF-β to its active form, which is one of the most important
mechanisms that regulate activation of the TGF-β signaling [31].
ROS may also regulate TGF-β signaling indirectly via certain
oxidative intermediate products. In cultured macrophages, treat-
ment with 4-hydroxy nonenal (4-HNE), a major reactive aldehyde
formed during lipid peroxidation, upregulated TGF-β expression
and release [32], although it was not clear whether the same effect
was also present in ﬁbroblasts. Moreover, ROS may have modulat-
ing effects on TGF-β-induced Smad2/3 activation. In cardiac ﬁbro-
blasts, it was observed that TGF-β-induced Smad2/3 phosphory-
lation was signiﬁcantly suppressed by various antioxidant agents
and by Nox4 gene silencing [18]. In a model of bleomycin-induced
pulmonary ﬁbrosis, the level of Smad2 phosphorylation was sig-
niﬁcantly decreased in Nox4 knockout mice [27]. In a separate study
in kidney proximal tubular epithelial cells, it was reported that
antioxidant treatment effectively inhibited TGF-β-induced phos-
phorylation of Smad2, although exogenous H2O2 failed to modulate
Smad2 phosphorylation [24]. Nox4 modulation of Smad2/3 phos-
phorylation was also observed in cultured pulmonary ﬁbroblasts
[25]. These ﬁndings together indicate that NADPH oxidase and ROS
molecules may have critical roles in facilitating TGF-β-induced
Smad2/3 activation.
The mechanism of the enhancing effect of ROS on TGF-β-
induced Smad phosphorylation is currently unclear. However,
several possibilities that may explain this phenomenon are pro-
posed. Activation of TGF-β signaling requires phosphorylation of
the type I receptor (ALK5) on serine and threonine residues in the
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Fig. 2. Involvement of Nox4 type NADPH oxidase in TGF-β-induced proﬁbrotic responses. Nox4-derived ROS facilitate TGF-β-mediated ﬁbrosis by inducing differentiation of
ﬁbroblasts into myoﬁbroblasts and synthesis of extracellular matrix proteins, while inhibiting their degradation. Nox4-derived ROS also promote apoptosis of epithelial cells.
It remains to be conﬁrmed whether Nox4 signaling is also involved in TGF-β-mediated epithelial to mesenchymal transition (EMT). It is proposed that selective inhibitors of
Nox4 such as GKT-136901 and compound 88 may represent a novel strategy to combat ﬁbrotic disorders. The inset illustrates the structure of the prototype Nox2.
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Fig. 3. Potential redox-dependent mechanisms that may be involved in modulating TGF-β-induced intracellular signaling. ROS may facilitate TGF-β signaling by
(1) promoting conversion of latent TGF-β to its active form; (2) enhancing phosphorylation of the TGF-β receptor I (ALK5); (3) enhancing phosphorylation of Smad2/3;
(4) enhancing JNK and p38 activation, leading to increased transcriptional activities of Smad proteins. PP1, protein phosphatase 1.
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Fig. 4. Potential mechanisms of TGF-β-induced upregulation of Nox4 gene expression. (A) TGF-β may stimulate Nox4 expression via the classical Smad2/3 pathway and
activation of the PI3K pathway. (B) A putative Smad binding motif (boxed) is present in the Nox4 gene promoter region, which is conserved in human, mouse and rat.
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GS domain upon ligand binding, while phosphorylated ALK5 in
turn induces phosphorylation of Smad2/3 in their C-terminal SXS
motif and thereby initiates downstream signaling events [33].
ALK5 phosphorylation is negatively regulated (dephosphorylated)
by protein phosphatase 1 (PP1) and PP2A [33]. There is evidence
showing that PP1 and PP2A are redox-sensitive, with ROS mole-
cules such as H2O2 being able to inactivate the activity of these
enzymes [34], leading to enhanced ALK5 activation and Smad
phosphorylation. Moreover, people have demonstrated that the
phosphatase PTEN may induce a decrease in Smad2/3 phosphor-
ylation, although this effect of PTEN appears to require another
phosphatase PPM1A [33]. It is well documented that PTEN
is sensitive to ROS-induced oxidation and inactivation [35]. In this
scenario, ROS may facilitate Smad phosphorylation by inhibiting
PTEN/PPM1A-mediated dephosphorylation. Nevertheless, the
importance of these potential mechanisms in modulating TGF-β
signaling in vivo is currently not understood, which needs to be
further corroborated by direct experimental evidence.
In addition to regulating Smad phosphorylation, ROS may also
modulate TGF-β signaling via non-canonical, Smad-independent
mechanisms. In addition to Smad-transduced signals, TGF-β may
activate other signaling pathways including the mitogen-activated
protein kinase (MAPK) members c-Jun N-terminal kinase (JNK)
and p38 [36]. Of note, it is clear that both JNK and p38 are redox
sensitive, which can be activated by ROS in the cytoplasm [35].
Interestingly, experimental evidence has indicated that JNK and
p38 may in turn enhance the transcriptional activities of Smad
proteins by direct phosphorylation of Smad3 or indirectly by pro-
moting Smad3 association with the transcriptional co-activator
p300 [36]. Hence, ROS may facilitate TGF-β-induced signaling by
enhancing JNK and p38 activation. These redox mechanisms
possibly involved in modulating TGF-β functions are summarized
in Fig. 3.
Mechanisms of TGF-β regulation of Nox4 expression
TGF-β upregulates Nox4 expression in a variety of cells [17,18,
20,37–40]. Two major mechanisms potentially involved in TGF-β-
induced Nox4 expression are the classical Smad2/3 pathway and
the phosphoinositide 3-kinase (PI3K) pathway (Fig. 4). We and
others have demonstrated that TGF-β-induced Nox4 upregulation
and ROS generation can be inhibited by inhibitors of ALK5 and
Smad3, or dormant negative mutants of Smad2/3 [17,37,40,41],
suggesting that Nox4 expression occurs downstream of Smad2/3
activation. Similarly, overexpression of the inhibitory Smad protein
Smad7 reversed the stimulating effects of TGF-β on Nox4 expres-
sion [41]. In addition to the Smad pathway, there is evidence
suggesting that activation of PI3K may also be involved in TGF-β-
induced regulation of Nox4 expression. For example, using a
pharmacological inhibitor of PI3K, Michaeloudes et al. showed
that in airway smooth muscle cells, PI3K inhibition abrogated
Nox4 expression in response to TGF-β treatment [41]. Moreover,
Sturrock et al. also demonstrated that TGF-β-stimulated Nox4
expression in airway smooth muscle cells was sensitive to PI3K
inhibition [42]. However, the role of PI3K in TGF-β-induced
modulation of Nox4 expression in ﬁbroblasts is currently unclear,
which needs to be further clariﬁed.
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